[go: up one dir, main page]

AR100942A1 - Composiciones y método para el control glucémico que comprenden albiglutida - Google Patents

Composiciones y método para el control glucémico que comprenden albiglutida

Info

Publication number
AR100942A1
AR100942A1 ARP150102004A ARP150102004A AR100942A1 AR 100942 A1 AR100942 A1 AR 100942A1 AR P150102004 A ARP150102004 A AR P150102004A AR P150102004 A ARP150102004 A AR P150102004A AR 100942 A1 AR100942 A1 AR 100942A1
Authority
AR
Argentina
Prior art keywords
polypeptide
albiglutide
compositions
liquid composition
variant
Prior art date
Application number
ARP150102004A
Other languages
English (en)
Inventor
P Nesta Douglas
Doucet Dany
Chang Liuquan
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of AR100942A1 publication Critical patent/AR100942A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones líquidas que comprenden albiglutida o una variante de la misma, un agente tamponante, al menos un sacárido y/o al menos un poliol, al menos un agente estabilizante y opcionalmente un tensioactivo en las que dicha albiglutida permanece estable en dicha composición líquida. La albiglutida o una variante de la misma permanece estable en líquido si al menos 96 % de dicha albiglutida o una variante de la misma permanece como un monómero en la composición líquida durante un período de al menos una semana. Reivindicación 1: Una composición líquida que comprende un polipéptido que tiene una identidad de secuencia de al menos 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% o 100% con el polipéptido expuesto en la SEC ID Nº 1 o un polipéptido que tiene una identidad de secuencia de al menos 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% o 100% con el polipéptido expuesto en la SEC ID Nº 1 que está truncado en el extremo C-terminal y/o extremo N-terminal al menos un agente tamponante al menos un sacárido y/o al menos un poliol, al menos un agente estabilizante y opcionalmente al menos un tensioactivo en el que dicho polipéptido permanece estable en dicha composición líquida.
ARP150102004A 2014-06-25 2015-06-23 Composiciones y método para el control glucémico que comprenden albiglutida AR100942A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462016806P 2014-06-25 2014-06-25

Publications (1)

Publication Number Publication Date
AR100942A1 true AR100942A1 (es) 2016-11-09

Family

ID=54938738

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102004A AR100942A1 (es) 2014-06-25 2015-06-23 Composiciones y método para el control glucémico que comprenden albiglutida

Country Status (13)

Country Link
US (3) US20180021409A1 (es)
EP (1) EP3160491A4 (es)
JP (1) JP2017524680A (es)
KR (1) KR20170021313A (es)
CN (1) CN106659770A (es)
AR (1) AR100942A1 (es)
AU (1) AU2015280110A1 (es)
BR (1) BR112016030588A2 (es)
CA (1) CA2952969A1 (es)
IL (1) IL249553A0 (es)
RU (1) RU2017101667A (es)
TW (1) TW201613630A (es)
WO (1) WO2015200324A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107661288A (zh) * 2016-07-29 2018-02-06 江苏泰康生物医药有限公司 含有glp‑1 类似物融合蛋白的稳定液体制剂及其制备
EP3518971A4 (en) * 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF
CN108210890A (zh) * 2016-12-09 2018-06-29 江苏泰康生物医药有限公司 重组人胰高血糖素样肽-1类似物融合蛋白的新型稳定制剂
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
GB201917723D0 (en) * 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
AU2021276071A1 (en) * 2020-05-22 2023-02-02 Hanmi Pharm. Co., Ltd. Liquid formulation
CU24723B1 (es) * 2021-01-29 2024-12-09 Ct Ingenieria Genetica Biotecnologia Composición farmacéutica que comprende el ghrp-6
WO2023246928A1 (zh) * 2022-06-23 2023-12-28 广州银诺医药集团股份有限公司 一种改进的glp-1受体激动剂的融合蛋白和应用
CN114984231B (zh) * 2022-06-28 2024-07-26 佛山汉腾生物科技有限公司 稳定性制剂及其制备方法
CN118256580B (zh) * 2022-12-27 2025-06-24 信立泰(苏州)药业有限公司 一种用于表达度拉糖肽的cho细胞的低温培养方法
US12427185B2 (en) 2023-09-05 2025-09-30 E-Star Biotech, LLC Formulations of MANP and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101308912B1 (ko) * 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
EP2373681B1 (en) * 2008-12-10 2017-01-18 Glaxosmithkline LLC Pharmaceutical compositions of albiglutide
WO2012074676A2 (en) * 2010-11-09 2012-06-07 Emory University Glp-1 agonists, dpp-4 inhibitors, compositions, and uses related thereto
SG192671A1 (en) * 2011-02-09 2013-09-30 Glaxosmithkline Llc Lyophilized formulations
US20120208755A1 (en) * 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers

Also Published As

Publication number Publication date
AU2015280110A1 (en) 2017-01-12
WO2015200324A1 (en) 2015-12-30
IL249553A0 (en) 2017-02-28
JP2017524680A (ja) 2017-08-31
TW201613630A (en) 2016-04-16
US20190175701A1 (en) 2019-06-13
US20180369341A1 (en) 2018-12-27
CN106659770A (zh) 2017-05-10
EP3160491A1 (en) 2017-05-03
EP3160491A4 (en) 2018-01-17
BR112016030588A2 (pt) 2017-10-31
KR20170021313A (ko) 2017-02-27
US20180021409A1 (en) 2018-01-25
RU2017101667A (ru) 2018-07-26
CA2952969A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
AR100942A1 (es) Composiciones y método para el control glucémico que comprenden albiglutida
MX2017008449A (es) Polipeptido de pirina y modulacion inmune.
CL2017000646A1 (es) Composiciones que contengan células de bacilo recombinantes y otro agente de control biológico
AR105766A1 (es) Polipéptidos que tienen actividad de pululanasa adecuados para usar en licuefacción
CL2017000999A1 (es) Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
BR112017005509A2 (pt) composições que compreendem células recombinantes de bacillus e um outro agente de controle biológico.
AR105470A1 (es) Métodos para inducir una respuesta inmune
PE20170471A1 (es) Polipeptidos receptores formulados y metodos relacionados
MX2017016518A (es) Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo.
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
MX2017010880A (es) Variantes de polipéptidos para el clivaje de la toxina fusario, aditivo que contiene las mismas, uso de las mismas, y método para el clivaje de las toxinas fusario.
MX383817B (es) Composiciones y metodos para controlar plagas de plantas.
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
PH12017501018A1 (en) Composition and methods for controlling plant pests
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
UY36332A (es) Composiciones de bacillus pumilus rt1279 y metodos de uso para benefficiar el crecimiento de las plantas
MX2016014633A (es) Nuevos derivados de cath2.
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
MX2015018028A (es) Composiciones de lagrimas artificiales.
MX2017007619A (es) Composiciones y metodos para controlar plagas en plantas.
MX2019002248A (es) Proteina de union al factor h modificada.
MX392412B (es) Polipéptidos que tienen actividad inductora de inmunidad.
MX2015011308A (es) Composicion de limpieza con una mejor eliminacion de la suciedad.
PH12020551582A1 (en) Lfa3 variants and compositions and uses thereof
MX365952B (es) Composiciones para la prevención y/o el tratamiento de patologías relacionadas con alfa-glucosidasa.

Legal Events

Date Code Title Description
FB Suspension of granting procedure